Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis

<div>MTT detection of hepatoma cell proliferation after NCTD-NLC treatment. (a) 24 h after treatment in each group, MTT assay was conducted to estimate cell viability. (b) After 48 h treatment in each group, MTT assay was conducted to estimate cell viability.</div>

Journal of Immunology Research

fig1

Figure 1

Figure 1: Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis 

Figure 1 | Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis 